OLD Category: CAR-T

Constitutive signaling from an engineered IL-7 receptor promotes durable tumor elimination by tumor redirected T-cells

• Thomas Shum et al.

IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy

• Ngai H et al.,

Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment

• Sukumaran S. et. al.,

Redirecting T-cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptor

• Caruso et. al.

Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells

• Shum T et al.,

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen

• S Rafiq et al.

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function

• Singh N et al.,

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen

• Rafiq S. et al.,

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

• Kebriaei P. et al.,

Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors

• Radhika Thokala et al.

Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123 Tumors

• Thokala R. et al.,

Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor

• Caruso H.G. et al.,